Literature DB >> 9687389

Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics.

G Wang1, D E Taylor.   

Abstract

Clarithromycin resistance in Helicobacter pylori is mainly due to A-to-G mutations within the peptidyltransferase region of the 23S rRNA. In the present study, cross-resistance to macrolide, lincosamide, and streptogramin B (MLS) antibiotics (MLS phenotypes) has been investigated for several clinical isolates of H. pylori. Two major types of MLS resistance were identified and correlated with specific point mutations in the 23S rRNA gene. The A2142G mutation was linked with high-level cross-resistance to all MLS antibiotics (type I), and the A2143G mutation gave rise to an intermediate level of resistance to clarithromycin and clindamycin but no resistance to streptogramin B (type II). In addition, streptogramin A and streptogramin B were demonstrated to have a synergistic effect on both MLS-sensitive and MLS-resistant H. pylori strains. To further understand the mechanism of MLS resistance in H. pylori, we performed in vitro site-directed mutagenesis (substitution of G, C, or T for A at either position 2142 or 2143 of the 23S rRNA gene). The site-directed point mutations were introduced into a clarithromycin-susceptible strain, H. pylori UA802, by natural transformation followed by characterization of their effects on MLS resistance in an isogenic background. Strains with A-to-G and A-to-C mutations at the same position within the 23S rRNA gene had similar levels of clarithromycin resistance, and this level of resistance was higher than that for strains with the A-to-T mutation. Mutations at position 2142 conferred a higher level of clarithromycin resistance than mutations at position 2143. All mutations at position 2142 conferred cross-resistance to all MLS antibiotics, which corresponds to the type I MLS phenotype, whereas mutations at position 2143 were associated with a type II MLS phenotype with no resistance to streptogramin B. To explain that A-to-G transitions were predominantly observed in clarithromycin-resistant clinical isolates, we propose a possible mechanism by which A-to-G mutations are preferentially produced in H. pylori.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687389      PMCID: PMC105715     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  The complete genome sequence of the gastric pathogen Helicobacter pylori.

Authors:  J F Tomb; O White; A R Kerlavage; R A Clayton; G G Sutton; R D Fleischmann; K A Ketchum; H P Klenk; S Gill; B A Dougherty; K Nelson; J Quackenbush; L Zhou; E F Kirkness; S Peterson; B Loftus; D Richardson; R Dodson; H G Khalak; A Glodek; K McKenney; L M Fitzegerald; N Lee; M D Adams; E K Hickey; D E Berg; J D Gocayne; T R Utterback; J D Peterson; J M Kelley; M D Cotton; J M Weidman; C Fujii; C Bowman; L Watthey; E Wallin; W S Hayes; M Borodovsky; P D Karp; H O Smith; C M Fraser; J C Venter
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

2.  Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA.

Authors:  J I Ross; E A Eady; J H Cove; C E Jones; A H Ratyal; Y W Miller; S Vyakrnam; W J Cunliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Antibiotic resistance mutations in ribosomal RNA genes of Escherichia coli.

Authors:  C D Sigmund; M Ettayebi; A Borden; E A Morgan
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

4.  Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

Authors:  J Versalovic; M S Osato; K Spakovsky; M P Dore; R Reddy; G G Stone; D Shortridge; R K Flamm; S K Tanaka; D Y Graham
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

5.  A plasmid-coded and site-directed mutation in Escherichia coli 23S RNA that confers resistance to erythromycin: implications for the mechanism of action of erythromycin.

Authors:  B Vester; R A Garrett
Journal:  Biochimie       Date:  1987-08       Impact factor: 4.079

Review 6.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 7.  Inhibition of protein synthesis by streptogramins and related antibiotics.

Authors:  C Cocito; M Di Giambattista; E Nyssen; P Vannuffel
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

8.  Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori.

Authors:  Y J Debets-Ossenkopp; M Sparrius; J G Kusters; J J Kolkman; C M Vandenbroucke-Grauls
Journal:  FEMS Microbiol Lett       Date:  1996-08-15       Impact factor: 2.742

9.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Authors:  J Versalovic; D Shortridge; K Kibler; M V Griffy; J Beyer; R K Flamm; S K Tanaka; D Y Graham; M F Go
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more
  41 in total

1.  Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae.

Authors:  F Depardieu; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

3.  Structural basis for selectivity and toxicity of ribosomal antibiotics.

Authors:  E C Böttger; B Springer; T Prammananan; Y Kidan; P Sander
Journal:  EMBO Rep       Date:  2001-04       Impact factor: 8.807

4.  Clarithromycin resistance in Helicobacter pylori and its clinical relevance.

Authors:  Hua-Xiang Xia; Xue-Gong Fan; Nicholas J Talley
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

5.  Fitness cost of chromosomal drug resistance-conferring mutations.

Authors:  Peter Sander; Burkhard Springer; Therdsak Prammananan; Antje Sturmfels; Martin Kappler; Michel Pletschette; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori.

Authors:  Christophe Burucoa; Cédric Landron; Martine Garnier; Jean-Louis Fauchère
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.

Authors:  Vanessa G Allen; David J Farrell; Anuradha Rebbapragada; Jingyuan Tan; Nathalie Tijet; Stephen J Perusini; Lynn Towns; Stephen Lo; Donald E Low; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

8.  Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.

Authors:  S Pereyre; P Gonzalez; B De Barbeyrac; A Darnige; H Renaudin; A Charron; S Raherison; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 9.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

10.  Genotypic characterization of clarithromycin-resistant and -susceptible Helicobacter pylori strains from the same patient demonstrates existence of two unrelated isolates.

Authors:  G Wang; Q Jiang; D E Taylor
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.